Persisting neuroendocrine abnormalities and their association with physical impairment 5 years after critical illness.
Adrenal axis
Critical illness
Long-term
Physical function
Somatotropic axis
Thyroid axis
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
16 12 2021
16 12 2021
Historique:
received:
16
09
2021
accepted:
06
12
2021
entrez:
17
12
2021
pubmed:
18
12
2021
medline:
21
1
2022
Statut:
epublish
Résumé
Critical illness is hallmarked by neuroendocrine alterations throughout ICU stay. We investigated whether the neuroendocrine axes recover after ICU discharge and whether any residual abnormalities associate with physical functional impairments assessed 5 years after critical illness. In this preplanned secondary analysis of the EPaNIC randomized controlled trial, we compared serum concentrations of hormones and binding proteins of the thyroid axis, the somatotropic axis and the adrenal axis in 436 adult patients who participated in the prospective 5-year clinical follow-up and who provided a blood sample with those in 50 demographically matched controls. We investigated independent associations between any long-term hormonal abnormalities and physical functional impairments (handgrip strength, 6-min walk distance, and physical health-related quality-of-life) with use of multivariable linear regression analyses. At 5-year follow-up, patients and controls had comparable serum concentrations of thyroid-stimulating hormone, thyroxine (T Five years after ICU admission, most hormones and binding proteins of the thyroid, somatotropic and adrenal axes had recovered. The residual long-term abnormality within the thyroid axis was identified as risk factor for long-term physical impairment, whereas that within the somatotropic axis may be a compensatory protective response. Whether targeting of the residual abnormality in the thyroid axis may improve long-term physical outcome of the patients remains to be investigated. Trial registration ClinicalTrials.gov: NCT00512122, registered on July 31, 2007 ( https://www.clinicaltrials.gov/ct2/show/NCT00512122 ).
Sections du résumé
BACKGROUND
Critical illness is hallmarked by neuroendocrine alterations throughout ICU stay. We investigated whether the neuroendocrine axes recover after ICU discharge and whether any residual abnormalities associate with physical functional impairments assessed 5 years after critical illness.
METHODS
In this preplanned secondary analysis of the EPaNIC randomized controlled trial, we compared serum concentrations of hormones and binding proteins of the thyroid axis, the somatotropic axis and the adrenal axis in 436 adult patients who participated in the prospective 5-year clinical follow-up and who provided a blood sample with those in 50 demographically matched controls. We investigated independent associations between any long-term hormonal abnormalities and physical functional impairments (handgrip strength, 6-min walk distance, and physical health-related quality-of-life) with use of multivariable linear regression analyses.
RESULTS
At 5-year follow-up, patients and controls had comparable serum concentrations of thyroid-stimulating hormone, thyroxine (T
CONCLUSIONS
Five years after ICU admission, most hormones and binding proteins of the thyroid, somatotropic and adrenal axes had recovered. The residual long-term abnormality within the thyroid axis was identified as risk factor for long-term physical impairment, whereas that within the somatotropic axis may be a compensatory protective response. Whether targeting of the residual abnormality in the thyroid axis may improve long-term physical outcome of the patients remains to be investigated. Trial registration ClinicalTrials.gov: NCT00512122, registered on July 31, 2007 ( https://www.clinicaltrials.gov/ct2/show/NCT00512122 ).
Identifiants
pubmed: 34915907
doi: 10.1186/s13054-021-03858-1
pii: 10.1186/s13054-021-03858-1
pmc: PMC8675467
doi:
Substances chimiques
Triiodothyronine
06LU7C9H1V
Thyroxine
Q51BO43MG4
Banques de données
ClinicalTrials.gov
['NCT00512122']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
430Subventions
Organisme : Research Foundation Flanders
ID : 1805121N
Organisme : Research Foundation Flanders
ID : G087920N
Organisme : Methusalem program of the Flemish government
ID : METH14/06
Organisme : FP7 Ideas: European Research Council
ID : AdvG-2012-321670
Organisme : H2020 European Research Council
ID : AdvG-2017-785809
Organisme : Onderzoeksraad, KU Leuven
ID : C2 project 24/17/070
Organisme : Onderzoeksraad, KU Leuven
ID : STG/15/041
Organisme : Universitaire Ziekenhuizen Leuven, KU Leuven
ID : Postdoctoral research fellowship
Informations de copyright
© 2021. The Author(s).
Références
J Clin Endocrinol Metab. 2018 Nov 1;103(11):3986-3992
pubmed: 30137405
Biochem Biophys Res Commun. 2018 Nov 30;506(3):597-603
pubmed: 30366665
J Clin Endocrinol Metab. 2005 Aug;90(8):4559-65
pubmed: 15886232
J Clin Endocrinol Metab. 2001 Sep;86(9):4198-205
pubmed: 11549650
Eur J Endocrinol. 2011 Feb;164(2):189-96
pubmed: 21135066
J Endocrinol. 2018 Jan;236(1):R57-R68
pubmed: 29051191
Intensive Care Med. 2020 Jun;46(6):1184-1193
pubmed: 31970446
Intensive Care Med. 2018 Dec;44(12):2048-2058
pubmed: 30374692
Front Pediatr. 2018 Jan 15;5:293
pubmed: 29379779
J Clin Endocrinol Metab. 1998 Jun;83(6):1827-34
pubmed: 9626104
N Engl J Med. 2004 Apr 15;350(16):1629-38
pubmed: 15084695
Crit Care. 2021 Mar 17;25(1):108
pubmed: 33731201
J Neurol Neurosurg Psychiatry. 2000 Jun;68(6):750-5
pubmed: 10811699
N Engl J Med. 2013 Apr 18;368(16):1477-88
pubmed: 23506003
Muscle Nerve. 2014 Sep;50(3):431-6
pubmed: 24415656
J Clin Endocrinol Metab. 2006 Oct;91(10):3803-13
pubmed: 16868064
Pituitary. 2019 Jun;22(3):249-260
pubmed: 30684166
JAMA. 2000 Feb 23;283(8):1038-45
pubmed: 10697064
Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):753-67
pubmed: 19942151
PLoS One. 2012;7(1):e30096
pubmed: 22253890
J Clin Endocrinol Metab. 2002 Jul;87(7):3118-24
pubmed: 12107211
Front Cell Dev Biol. 2020 May 05;8:286
pubmed: 32478064
Nat Clin Pract Endocrinol Metab. 2008 Sep;4(9):496-505
pubmed: 18695699
Ann Clin Biochem. 2021 Jan;58(1):29-37
pubmed: 33040575
Pituitary. 2019 Jun;22(3):261-269
pubmed: 30929220
Neurobiol Aging. 2018 Jun;66:68-74
pubmed: 29547749
Shock. 2007 May;27(5):461-5
pubmed: 17438449
Pituitary. 2019 Jun;22(3):201-211
pubmed: 30927184
J Phys Ther Sci. 2019 Jan;31(1):75-78
pubmed: 30774209
J Clin Endocrinol Metab. 2003 Jul;88(7):3202-11
pubmed: 12843166
J Clin Endocrinol Metab. 2005 Dec;90(12):6403-9
pubmed: 16174720
Crit Care Med. 2003 Apr;31(4):1012-6
pubmed: 12682465
J Clin Endocrinol Metab. 2019 Nov 1;104(11):5507-5518
pubmed: 31361307
Arch Phys Med Rehabil. 2020 Mar;101(3):553-565
pubmed: 31730754
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-9
pubmed: 33793312
Clin Endocrinol (Oxf). 1991 Jul;35(1):47-54
pubmed: 1909610
Endocr Rev. 2009 Aug;30(5):417-37
pubmed: 19477944
Eur J Endocrinol. 2012 Nov;167(5):719-26
pubmed: 22956557
Intensive Care Med. 2020 Apr;46(4):637-653
pubmed: 32076765
Sci Rep. 2016 Jul 14;6:29334
pubmed: 27411715
Thorax. 2019 Nov;74(11):1037-1045
pubmed: 31481633
Thorax. 2019 Nov;74(11):1091-1098
pubmed: 31431489
J Neurooncol. 2016 Jul;128(3):473-9
pubmed: 27115743
J Gerontol A Biol Sci Med Sci. 2014 Feb;69(2):174-81
pubmed: 23811185
Am J Physiol Endocrinol Metab. 2006 Oct;291(4):E829-34
pubmed: 16684849
Eur J Endocrinol. 2009 Feb;160(2):157-63
pubmed: 19022915
Endocr Rev. 2002 Feb;23(1):38-89
pubmed: 11844744
Lancet Respir Med. 2013 Oct;1(8):621-629
pubmed: 24461665
Neuroscience. 2002;112(2):383-9
pubmed: 12044455
J Clin Endocrinol Metab. 1995 Apr;80(4):1238-42
pubmed: 7714094
Am J Physiol Endocrinol Metab. 2014 Apr 15;306(8):E883-92
pubmed: 24569590
J Eval Clin Pract. 2017 Apr;23(2):377-381
pubmed: 27592691
Trials. 2011 Jan 24;12:21
pubmed: 21261975
Aging Clin Exp Res. 2019 Aug;31(8):1113-1120
pubmed: 30367448
Endocrine. 2020 Nov;70(2):348-355
pubmed: 32346815
Am J Respir Crit Care Med. 2016 Dec 1;194(11):1337-1348
pubmed: 27611700
Intensive Care Med. 2020 Jan;46(1):70-81
pubmed: 31713058
N Engl J Med. 2011 Aug 11;365(6):506-17
pubmed: 21714640
J Clin Endocrinol Metab. 2013 Mar;98(3):1006-13
pubmed: 23348400
Eur J Endocrinol. 2003 Jun;148(6):627-34
pubmed: 12773134
Intensive Care Med. 2018 Oct;44(10):1720-1729
pubmed: 30215187
Psychoneuroendocrinology. 2020 Jul;117:104679
pubmed: 32353815
Nat Commun. 2015 Dec 15;6:10145
pubmed: 26666572
Best Pract Res Clin Endocrinol Metab. 2001 Dec;15(4):421-34
pubmed: 11800515
Am J Respir Crit Care Med. 2016 Oct 1;194(7):821-830
pubmed: 27058306
Brain Res. 2009 Oct 13;1293:114-20
pubmed: 19376097
Elife. 2019 Dec 03;8:
pubmed: 31793435
Am J Physiol Endocrinol Metab. 2003 Jun;284(6):E1149-55
pubmed: 12604504
Eur Child Adolesc Psychiatry. 2017 May;26(5):511-519
pubmed: 27995329
J Am Med Dir Assoc. 2019 Oct;20(10):1236-1241
pubmed: 31422066